The recently initiated large-sized FLOW trial investigating the effects of semaglutide on hard renal outcomes in patients with DKD will provide clarity whether GLP-1 receptor agonists may reduce the burden of DKD in addition to their other beneficial metabolic and cardiovascular effects
Although overall findings support a cardioprotective effect of GLP-1 RAs, the ITCA 650 trial showed directionally higher hazard ratios for several outcomes
Peptide therapy is a regenerative option for soft tissue injuries, tendon strains, and chronic inflammation
To make them work, they come with significant restrictions: you must take them on a completely empty stomach with a tiny sip of water, and wait a strict 30 minutes before consuming anything else
Weight regain after stopping GLP-1 medications is common, though data specific to retatrutide discontinuation is limited
Phase four, starting around month two to three post-medication, involves finding your sustainable carbohydrate threshold